Menu
Back to User profile » Dr Huifeng Zhu
Papers published by Dr Huifeng Zhu:
Feasibility of Catalpol Intranasal Administration and Its Protective Effect on Acute Cerebral Ischemia in Rats via Anti-Oxidative and Anti-Apoptotic Mechanisms
Wang J, Zhang Y, Zhang M, Sun S, Zhong Y, Han L, Xu Y, Wan D, Zhang J, Zhu H
Drug Design, Development and Therapy 2022, 16:279-296
Published Date: 25 January 2022
The Pivotal Role of Microbiota in Modulating the Neuronal–Glial–Epithelial Unit
Luo S, Zhu H, Zhang J, Wan D
Infection and Drug Resistance 2021, 14:5613-5628
Published Date: 21 December 2021
The Impact of Gut Microbiota Disorders on the Blood–Brain Barrier
Tang W, Zhu H, Feng Y, Guo R, Wan D
Infection and Drug Resistance 2020, 13:3351-3363
Published Date: 29 September 2020
Catalpol Enhances Neurogenesis And Inhibits Apoptosis Of New Neurons Via BDNF, But Not The BDNF/Trkb Pathway
Zhu HF, Shao Y, Qin L, Wang JH, Feng S, Jiang YB, Wan D
Drug Design, Development and Therapy 2019, 13:4145-4157
Published Date: 10 December 2019
Staphyloxanthin: a potential target for antivirulence therapy
Xue L, Chen YY, Yan Z, Lu W, Wan D, Zhu H
Infection and Drug Resistance 2019, 12:2151-2160
Published Date: 17 July 2019
Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX/BCL2 ratio via mTOR pathway
Wang Y, Shao YL, Gao YQ, Wan GR, Wan D, Zhu HF, Qiu Y, Ye XY
Drug Design, Development and Therapy 2019, 13:243-253
Published Date: 31 December 2018
Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver
Feng S, Qiu B, Zou L, Liu K, Xu X, Zhu H
Drug Design, Development and Therapy 2018, 12:4033-4046
Published Date: 23 November 2018